Search company, investor...

Hinova Pharmaceuticals

Founded Year




Total Raised


Date of IPO


About Hinova Pharmaceuticals

Hinova Pharmaceuticals (688302.SH) is a high-tech company that relies on technology platforms such as Sui Dynasty, PROTAC, and preparations to develop major new drug varieties with broad market potential. The company develops drugs for prostate cancer, breast tumor, gout, and other diseases that are clinically tested or within different research phases. The company was founded in 2013 and is based in Chengde, China.

Headquarters Location

Unit 1, 4/F, Building A 5 Keyuan South Rd, Gaoxin District

Chengdu, Sichuan, 610041,



Missing: Hinova Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Hinova Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Hinova Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Hinova Pharmaceuticals is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Hinova Pharmaceuticals Patents

Hinova Pharmaceuticals has filed 19 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Antiandrogens
  • Clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Lymphoma, Abandoned drugs, Oncology, Fluoroarenes, Molecular biology


Application Date


Grant Date



Related Topics

Lymphoma, Abandoned drugs, Oncology, Fluoroarenes, Molecular biology



Latest Hinova Pharmaceuticals News

Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment

Feb 6, 2023

Hinova Receives FDA Proceed Authorization for its IND Application for HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment Share: WILMINGTON, Del., Feb. 6, 2023 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focusing on developing novel therapeutics for cancers and metabolic diseases, recently announced that the U.S. Food and Drug Administration (FDA) has cleared the company's investigational new drug application (IND) for its innovative drug HP518, an oral chimeric degrader targeting androgen receptor (AR) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). HP518 is currently in Phase I clinical trials in Australia. The open-label study approved by FDA will assess the safety, pharmacokinetics, and anti-tumor activity of HP518. "HP518 is a novel drug expected to address the unmet clinical needs of prostate cancer treatment," said Yuanwei Chen, Ph.D., President and CEO of Hinova. "The available study results of HP518 strengthen our confidence that HP518 is a potentially new treatment for drug resistant prostate cancer. We are making full efforts to advance the clinical study, hoping HP518 will provide more clinical benefits to patients worldwide in the future." HP518 has been discovered and developed through Hinova's targeted protein degradation drug discovery platform. It has the potential to overcome the drug resistance of prostate cancer that is due to some specific AR mutations. AR is a validated therapeutic target to treat prostate cancer. During the treatment of prostate cancer, drug resistance becomes inevitable due to multiple mechanisms, including AR amplification or mutations, etc. In preclinical studies, HP518 showed excellent selectivity and degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide. HP518 also demonstrated excellent antitumor efficacy in xenograft mouse models. About Hinova Hinova is an international and clinical-stage biopharmaceutical company engaged in the development of innovative deuterated and chimeric degraders for cancers and metabolic diseases. The company has established a targeted protein degradation drug discovery platform, which allows Hinova to screen for protein degradation activity rapidly and to accomplish efficient design and optimization of chimeric degraders. Furthermore, Hinova has profound experience in chemical manufacturing control (CMC) of Chimeric degrader compounds. For more information, please visit . View original content:

Hinova Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Hinova Pharmaceuticals founded?

    Hinova Pharmaceuticals was founded in 2013.

  • Where is Hinova Pharmaceuticals's headquarters?

    Hinova Pharmaceuticals's headquarters is located at Unit 1, 4/F, Building A, Chengdu.

  • What is Hinova Pharmaceuticals's latest funding round?

    Hinova Pharmaceuticals's latest funding round is IPO.

  • How much did Hinova Pharmaceuticals raise?

    Hinova Pharmaceuticals raised a total of $186.88M.

  • Who are the investors of Hinova Pharmaceuticals?

    Investors of Hinova Pharmaceuticals include DiNova Venture Partners, Founder H Fund, Shenzhen Investment Holdings, Guohai Innovative CCI Capital, China Capital Investment Group and 19 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.